MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejendo/lvag164

Медицинская библиотека · European journal of endocrinology · 2026

Metyrapone-associated improvements in health-related quality of life in Cushing's syndrome.

Mezôsi Emese, Nieman Lynnette K, Scaroni Carla, Boscaro Marco, Deutschbein Timo, Driessens Natacha, Georgescu Carmen E, Motyka Marcin, Hubalewska-Dydejczyk Alicja, Jarzab Barbara, Maiter Dominique, Reincke Martin, Loli Paola, Zampetti Benedetta, Atmaca Aysegul, Badiu Corin, Beckers Albert, Bolanowski Marek, Cavagnini Francesco, Unger Nicole, Giordano Roberta, Hanzu Felicia Alexandra, Terzolo Massimo, Domenech Arnau, Nader Myriam Bou, Sinaii Ninet, Tőke Judit, Tóth Miklós

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

This analysis describes the evolution of health-related quality of life (HRQoL) over 36 weeks of metyrapone treatment in the PROMPT study, identifying patterns of early, delayed improvement, or persistence using item-level resolution.

DESIGN AND

METHODS

Longitudinal analysis of patient-reported outcomes from PROMPT (NCT02297945), a prospective, open-label, multicountry study of metyrapone in 49 evaluable adults with confirmed endogenous CS. HRQoL was assessed with the CushingQoL (0-100; higher = better QoL) and Tübingen CD-25 (0-100; higher = worse QoL) at weeks 4, 12, 24, and 36. Item-level analyses characterized the pattern and timing of improvement. Within-patient changes were assessed using the Wilcoxon signed-rank test.

RESULTS

Both questionnaires demonstrated significant overall improvement by week 36: CushingQoL increased by 10.4 points (P < .001; 44.7% with ≥10-point improvement), and Tübingen CD-25 decreased by -7.8 points (P = .01). Early responses (by week 12) involved eating behaviour and depression symptoms. Delayed improvements (consolidating at weeks 24-36) were observed in sexual activity, environment, and social domains. Bodily restrictions (-4.3 points, P = .203) and cognition (-6.8 points, P = .143) did not show improvement over the study period. Item-level analysis identified a cluster of symptoms, predominantly psychological health anxiety and physical appearance concerns, where burden remained elevated throughout the 36 weeks despite cortisol normalization.

CONCLUSIONS

Metyrapone treatment is associated with meaningful, progressive HRQoL improvements across multiple symptom domains over 36 weeks, with a pattern consistent with rapid cortisol-mediated relief (eating, mood), delayed recovery in social and sexual domains, and persistent residual burden in symptom clusters likely driven by incomplete phenotypic reversal within the study timeframe.

Для цитирования: Mezôsi Emese, Nieman Lynnette K, Scaroni Carla, Boscaro Marco, Deutschbein Timo, Driessens Natacha, Georgescu Carmen E, Motyka Marcin, Hubalewska-Dydejczyk Alicja, Jarzab Barbara, Maiter Dominique, Reincke Martin, Loli Paola, Zampetti Benedetta, Atmaca Aysegul, Badiu Corin, Beckers Albert, Bolanowski Marek, Cavagnini Francesco, Unger Nicole, Giordano Roberta, Hanzu Felicia Alexandra, Terzolo Massimo, Domenech Arnau, Nader Myriam Bou, Sinaii Ninet, Tőke Judit, Tóth Miklós. Metyrapone-associated improvements in health-related quality of life in Cushing's syndrome.. European journal of endocrinology. 2026. DOI: 10.1093/ejendo/lvag164.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.